Israel's IceCure Medical said on Sunday it received U.S. regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous tumours in livers and kidneys, sending its share price up 30%.
IceCure's treatment uses special needles to inject liquid nitrogen to freeze and destroy tumours without the need for surgery.
It has focused on breast tumours, but now the U.S. Food and Drug Administration (FDA) approved new uses, such as against tumours in the kidney, liver and in the fields of neurology and ear, nose and throat, the company said.
The FDA also approved its new MultySense system that has three probes, it said. Its earlier system had one needle.
